1. Alzheimer's vulnerable brain region relies on a distinct retromer core dedicated to endosomal recycling.
- Author
-
Simoes S, Guo J, Buitrago L, Qureshi YH, Feng X, Kothiya M, Cortes E, Patel V, Kannan S, Kim YH, Chang KT, Hussaini SA, Moreno H, Di Paolo G, Andersen OM, and Small SA
- Subjects
- Adult, Aged, Aged, 80 and over, Alzheimer Disease genetics, Alzheimer Disease metabolism, Animals, Brain metabolism, Case-Control Studies, Endosomes metabolism, Female, Humans, LDL-Receptor Related Proteins genetics, Male, Membrane Transport Proteins genetics, Mice, Mice, Inbred C57BL, Mice, Knockout, Middle Aged, Neuroimaging, Protein Transport, Vesicular Transport Proteins chemistry, Vesicular Transport Proteins genetics, Alzheimer Disease pathology, Brain pathology, Endosomes pathology, LDL-Receptor Related Proteins metabolism, Membrane Transport Proteins metabolism, Vesicular Transport Proteins metabolism, Vesicular Transport Proteins physiology
- Abstract
Whether and how the pathogenic disruptions in endosomal trafficking observed in Alzheimer's disease (AD) are linked to its anatomical vulnerability remain unknown. Here, we began addressing these questions by showing that neurons are enriched with a second retromer core, organized around VPS26b, differentially dedicated to endosomal recycling. Next, by imaging mouse models, we show that the trans-entorhinal cortex, a region most vulnerable to AD, is most susceptible to VPS26b depletion-a finding validated by electrophysiology, immunocytochemistry, and behavior. VPS26b was then found enriched in the trans-entorhinal cortex of human brains, where both VPS26b and the retromer-related receptor SORL1 were found deficient in AD. Finally, by regulating glutamate receptor and SORL1 recycling, we show that VPS26b can mediate regionally selective synaptic dysfunction and SORL1 deficiency. Together with the trans-entorhinal's unique network properties, hypothesized to impose a heavy demand on endosomal recycling, these results suggest a general mechanism that can explain AD's regional vulnerability., Competing Interests: Declaration of interests S.A.S. is a co-founder of Retromer Therapeutics, has equity in the company, and is a paid consultant to the company. In addition, S.A.S. has equity in Imij Technologies, an MRI-based company. G.D.P. is a full-time employee of Denali Therapeutics, Inc. O.M.A. has commercial interests in Retromer Therapeutics. Lastly, S.A.S., S.S., and Y.H.Q. are listed as co-inventors on Columbia University-owned patents that relate to retromer biomarkers and retromer drug discovery targets., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF